严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的研究进展、2019冠状病毒病（COVID-19）的诊断与临床治疗
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19.
作者信息
Li Yang, Lu Si-Ming, Wang Jia-Long, Yao Hang-Ping, Liang Li-Guo
机构信息
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
出版信息
Heliyon. 2024 Jun 17;10(12):e33179. doi: 10.1016/j.heliyon.2024.e33179. eCollection 2024 Jun 30.
BACKGROUND
Corona Virus Disease 2019(COVID-19)is a global pandemic novel coronavirus infection disease caused by Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Although rapid, large-scale testing plays an important role in patient management and slowing the spread of the disease. However, there has been no good and widely used drug treatment for infection and transmission of SARS-CoV-2.
KEY FINDINGS
Therefore, this review updates the body of knowledge on viral structure, infection routes, detection methods, and clinical treatment, with the aim of responding to the large-section caused by SARS-CoV-2. This paper focuses on the structure of SARS-CoV-2 viral protease, RNA polymerase, serine protease and main proteinase-like protease as well as targeted antiviral drugs.
CONCLUSION
or clinical trials have been carried out to provide deeper thinking for the pathogenesis, clinical diagnosis, vaccine development and treatment of SARS-CoV-2.
背景
2019年冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种全球大流行的新型冠状病毒感染疾病。尽管快速、大规模检测在患者管理和减缓疾病传播方面发挥着重要作用。然而，对于SARS-CoV-2的感染和传播，目前尚无良好且广泛应用的药物治疗方法。
主要发现
因此，本综述更新了关于病毒结构、感染途径、检测方法和临床治疗的知识体系，旨在应对由SARS-CoV-2引起的大面积问题。本文重点关注SARS-CoV-2病毒蛋白酶、RNA聚合酶、丝氨酸蛋白酶和类主蛋白酶的结构以及靶向抗病毒药物。
结论
已开展临床试验，为SARS-CoV-2的发病机制、临床诊断、疫苗研发和治疗提供更深入的思考。
Zotero 插件